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Abstract  Non-cystic  ﬁbrosis  bronchiectasis  remains  a  common  and  important  respiratory  dis-
ease to  date.  It  is  a  chronic  pathology  and  consequently  the  patients  usually  require  continuous
treatment.
In recent  decades  therapies  that  do  not  have  scientiﬁc  evidence  of  their  beneﬁts  have  been
commonly  used  in  non-cystic  ﬁbrosis  bronchiectasis.  Cystic  ﬁbrosis  has  provided  the  experience
to extrapolate  therapeutic  approaches  to  other  bronchiectasis  patients.  Finally,  in  the  last  few
years some  trials  have  been  carried  out  speciﬁcally  in  non-cystic  ﬁbrosis  bronchiectasis  which
aim to  assess  the  efﬁcacy  of  some  of  the  treatments  which  are  commonly  used  but  sometimes
without clear  indication.
This  review  will  discuss  the  recent  results  from  these  trials,  namely  mucoactive,  anti-
inﬂammatory  and  antibiotic  therapy.  Several  trials  are  ongoing  and  we  hope  they  will  be  able
to add  clariﬁcation  to  the  management  of  these  patients.
© 2013  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
PALAVRAS-CHAVE
Bronquiectasia
não-ﬁbrose  cística;
Avanc¸os;
Mucoactivo;
Novos  avanc¸os no  tratamento  da  Bronquiectasia  não-ﬁbrose  cística
Resumo  As  bronquiectasias  não-ﬁbrose  quística  continuam  a  ser  uma  doenc¸a  respiratória
comum e  importante.  Trata-se  de  uma  patologia  crónica  e,  consequentemente,  os  doentes
geralmente  precisam  de  um  tratamento  contínuo.Anti-inﬂamatório;
Antibiótico;
Terapia
Nas  últimas  décadas,  tratamentos  sem  evidência  cientíﬁca  dos  seus  benefícios  foram  comu-
mente usadas  nas  bronquiectasias  não-ﬁbrose  quística.  A  ﬁbrose  quística  serviu  de  experiência
para extrapolar  a  abordagem  terapêutica  para  outros  doentes  com  bronquiectasias.  Finalmente,
nos últimos  anos,  foram  realizados  alguns  ensaios  bronquiectasias  não-ﬁbrose  quística  que  visam
avaliar a  eﬁcácia  de  alguns  dos  tratamentos  que  são  comummente  usados  mas  por  vezes  sem
uma clara  indicac¸ão.
∗ Corresponding author.
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873-2159/$  –  see  front  matter  ©  2013  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.  All  rights  reserved.
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Nesta  revisão  serão  apresentados  os  resultados  recentes  destes  ensaios,  nomeadamente  sobre
o tratamento  mucoactivo,  anti-inﬂamatório  e  antibiótico.  Diversos  estudos  estão  a  decorrer  e
esperamos  que  estes  venham  a  esclarecer  a  abordagem  mais  adequada  destes  doentes.
© 2013  Sociedade  Portuguesa  de  Pneumologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
direitos reservados.
Table  1  Comparison  between  mannitol  and  hypertonic
saline.
Hyperosmolar  agent Mannitol  Hypertonic  saline
Dose  400  mg  bid  6  or  7%  bid
Delivery  By  an  inhaler By  nebulizer
Duration  of  effect Sustained  (up Short
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Bronchiectasis  (BE)  is  an  abnormal  and  irreversible  dilation
of  the  bronchi,  which  has  numerous  causes.  Its  frequency
depends  on  the  patient’s  age  and  sex,  social  and  economic
conditions  and  the  degree  of  applied  investigation.
There  was  little  interest  in  the  investigation  of  non-
cystic  ﬁbrosis  BE,  this  includes  therapeutic  approaches,
in  the  last  few  decades,  probably  due  to  supposedly  low
prevalence  and  the  assumption  that  treatment  is  the  same
for  all  patients  and  that  little  can  be  done  to  change  the
symptoms  and  evolution.
The  publication  of  diagnosis  and  treatment  reviews  in
the  last  few  years1,2 demonstrates  a  growing  interest  in  this
pathology.  The  level  of  evidence  for  most  recommendations
however  is  low,  because  of  the  absence  of  large  double-
blind,  placebo-controlled  trials.3,4
The  existence  of  strong  evidence  supporting  the  use  of
some  drugs  in  patients  with  cystic  ﬁbrosis  (CF)  does  not  mean
that  they  will  be  good  for  patients  with  BE  of  another  etiol-
ogy.  So,  it  is  not  correct  to  extrapolate  the  CF  trial  results
to  the  non-CF  patients.
In  CF,  the  forced  expiratory  volume  in  1  s  (FEV1)  is  one
of  the  most  important  trial  end-points.  In  non-CF  BE  it  has
been  difﬁcult  to  establish  appropriate  end-points  to  evalu-
ate  the  effect  of  new  therapeutic  interventions.  To  date  it
seems  that  improvement  in  quality  of  life  is  one  of  the  most
important  outcome  measures.5
BE  is  characterized  by  a  vicious  cycle  of  infection,  inﬂam-
mation  and  further  sputum  production.  In  this  review  we
decided  to  focus  on  three  important  pharmacological  groups
that  aim  to  interfere  with  each  part  of  the  cycle  and  in
which  there  have  been  relevant  advances.  Nevertheless,
BE  treatment  should  be  embraced  and  speciﬁc  therapies
for  the  underlying  cause  as  well  as  interventions  like
physiotherapy,  pulmonary  rehabilitation,  nutritional  support
and,  in  selected  patients,  surgical  intervention  need  to  be
kept  in  mind.
Mucoactive therapy
Regardless  of  the  cause,  BE  is  mainly  characterized  by
bronchial  infection  and  persistent  inﬂammation  which  could
be  the  cause  and  consequence  of  impaired  airway  mucous
clearance.  The  mucus  progressively  becomes  viscous  due
to  the  presence  of  inﬂammatory  cells,  microorganisms  and
large  polymers  and  turns  into  sputum,  overwhelming  the
ciliary  clearance  capacity.6
The  mucus  clearance  requires  a  balance  between  peri-
ciliary  liquid  volume,  mucus  composition  and  volume  and
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ito  24  h)
ormal  ciliary  beat  frequency.6 One  of  these  steps  could
e  more  particularly  affected  depending  on  the  cause  of
E;  the  therapeutic  intervention  should  ideally  be  focused
n  the  main  mechanism.7 Unfortunately  in  many  cases  this  is
ot  clear  and  there  is  probably  a  mix  of  mechanisms  involved
o  the  development  of  combined  therapies  would  be  more
ppropriate.
The  pathogenesis  process  mostly  accepted  in  CF  indicates
 relative  dehydration  and  a  reduction  in  airway  surface
iquid  volume.8 Therefore  airway  hydration  is  an  important
oal  in  the  overall  therapeutic  management  of  this  disease.
owever,  it  is  generally  accepted  that  even  in  the  absence  of
ehydration  the  increase  in  water  improves  mucus  clearance
y  decreasing  surface  interactions.9 In  this  context  the  most
ecent  advances  in  the  treatment  of  mucociliary  dysfunction
re  targeted  at  increasing  hydration  on  airway  surface  by
nhaled  hyperosmolar  agents,  like  mannitol  and  hypertonic
aline  (Table  1).  Both  the  agents  increase  the  osmolarity  of
he  airway  surface  ﬂuid  causing  inﬂux  of  water  into  the  air-
ay  and  reducing  the  viscoelastic  properties  of  the  mucus
y  breaking  some  of  the  mucin  bonds.10
As  inhalation  of  hyperosmolar  agents  may  induce  airway
arrowing  and  a  reduction  in  FEV1  of  about  15%  in  sensitive
ubjects,  an  assessment  of  bronchial  hyperresponsiveness  is
ecommended  before  starting  treatment.11,12
annitol
annitol  is  a  nonionic  sugar  alcohol,  commonly  used  as  an
smotic  agent,  which  increases  mucus  clearance.  The  pre-
ise  mechanism  of  this  action  is  unknown.9 Studies  have
emonstrated  that  the  effect  of  mannitol  is  acute  rather
han  cumulative  but  it  has  a  sustained  effect  for  up  to
4  h.  The  mucociliary  clearance  effect  was  also  found  in  all
egions  of  the  lung,  including  the  peripheral  region.13
Mannitol  capsules  (40  mg)  which  contain  dry  powder
or  inhalation  using  an  inhaler  device  are  commercially
vailable.12 They  have  been  approved  for  the  treatment
f  CF  in  adults  aged  ≥18  years.  The  recommended  dose
s  400  mg  (which  requires  the  inhalation  of  the  content  of
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0  capsules  loaded  individually  into  the  inhaler)  twice  a day,
nce  in  the  morning  and  once  in  the  evening.12 Mannitol  has
he  advantage  of  being  a  powder  formulation  and  therefore
as  a  shorter  delivery  time  which  avoids  the  usual  mainte-
ance  and  cleaning  issues  related  with  nebulizer  devices.
An  international  phase-III  randomized  double-blind
lacebo-controlled  trial  of  inhaled  dry  powder  mannitol
400  mg)  was  carried  out  on  324  CF  patients,  for  a  26-week
eriod,  twice  daily.  This  showed  a  signiﬁcant  improvement
n  FEV1  (change  from  baseline  118  mL  (6.5%)  versus  26  mL
2.4%);  p  <  0.001).  Improvements  in  FEV1  were  seen  fairly
arly  (at  6  weeks)  and  were  maintained  up  to  52  weeks.
here  was  also  a  35.4%  reduction  in  the  incidence  of  exac-
rbation  on  the  mannitol  group.  It  is  worth  noting  that  the
ung  function  improvement  was  found  irrespective  of  the
oncomitant  use  of  recombinant  human  deoxyribonuclease
rhDNase).  Cough  and  haemoptysis  were  the  most  common
dverse  events.  Overall  they  were  mild  or  moderate  and
nly  a  small  proportion  of  patients  had  to  discontinue  the
reatment.14
Given  these  results,  mannitol  was  also  tested  on  non-CF
E  and  even  though  the  ﬁrst  studies  were  carried  out  on
mall  groups  of  patients,  during  short  periods  of  time  and
ostly  relating  to  non-clinical  issues,  they  showed  promising
esults  of  its  use  in  this  patient  population.11
An  open-label  study  of  mannitol  (400  mg),  carried  out
n  9  patients  with  BE,  once  daily,  during  a  12-day  period
ocumented  a  highly  signiﬁcant  improvement  in  quality  of
ife,  which  is  assessed  by  St  George’s  Respiratory  Question-
aire  (SGRQ),  and  maintained  for  6--10  days  after  cessation
f  treatment.  It  is  important  to  note  that  patients  reported
 reduction  in  cough  during  both  day  and  night,  a  reduc-
ion  of  sputum  in  the  morning  and  an  increase  in  sleeping
ime.  Some  properties  of  sputum  were  changed,  increasing
ough  efﬁcacy.  No  signiﬁcant  changes  in  lung  function  were
ound.9 A  phase-3  multicentre  randomized  controlled  trial,
vailable  only  in  abstract,  involving  185  BE  patients  with
ild-to-moderate  lung  function  demonstrated  an  improve-
ent  in  health-related  quality  of  life  with  inhaled  mannitol
320  mg)  over  12  weeks.  Furthermore  a  prolonged  time  free
f  antibiotics  and  a  lower  total  use  of  antibiotics  compared
ith  placebo  was  observed.15
A  phase-III  clinical  trial  is  in  progress  and  the  purpose  of
his  study  is  to  examine  the  efﬁcacy  and  safety  of  a  52-week
reatment  with  400  mg  inhaled  mannitol,  twice  daily,  against
 control  group.  The  primary  outcome  measure  is  the  effect
f  mannitol  in  reducing  the  pulmonary  exacerbations  and
he  secondary  outcomes  are  the  difference  in  quality  of  life,
ntibiotic  use,  number  of  hospitalizations,  sputum  volume,
aytime  sleepiness  scores,  lung  function  and  health  related
osts.16
ypertonic  saline  solution
ypertonic  saline  (HS)  is  an  ionic  substance  quickly  trans-
orted  across  the  epithelium  and  delivered  using  an
ltrasonic  or  jet  nebulizer.  The  highest  well  tolerated
oncentration  is  7%.  Its  utility  was  well  documented  for  CF  in
 randomized  placebo-controlled  trial  in  164  patients,  twice
aily,  over  48  weeks.  The  HS  group  had  signiﬁcantly  fewer
ulmonary  exacerbations,  an  improvement  in  quality  of  life,
t
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 reduction  in  absenteeism  from  school  and  work  and  an
mprovement  in  FEV1  of  65  ml.17 A  Cochrane  review  in  2009,
ncluding  12  trials,  concluded  that  HS  is  a  safe,  low-cost  and
ffective  therapy  in  CF.18However,  the  HS  recommendation
or  non-CF  BE  is  not  clear.
In  a  crossover  trial  24  BE  patients,  who  produced  less
han  10  g  of  sputum  per  day,  were  randomly  selected
o  receive  four  single  treatment  schedules  once  a  week,
or  4  weeks.  This  included  active  cycle  breathing  tech-
ique  (ACBT)  alone;  nebulized  terbutaline  followed  by  ACBT
fter  10  min;  nebulized  terbutaline  followed  after  10  min
y  nebulized  isotonic  saline  (IS)  (09%)  then  ACBT;  nebu-
ized  terbutaline  followed  after  10  min  by  nebulized  HS
7%)  then  ACBT.  Both  nebulized  IS  and  HS  were  signiﬁcantly
ore  effective  in  increasing  sputum  yield,  reducing  sputum
iscosity  and  improving  ease  of  expectoration  but  HS  was
igniﬁcantly  better  than  IS.19
In  another  randomized  single  blind  crossover  trial  to  eval-
ate  IS  and  HS  daily  for  3  months  in  28  BE  patients,  a
igniﬁcant  improvement  in  lung  function  (FEV1  and  FVC)  and
uality  of  life  was  documented  by  changes  in  global  scores
nd  subscales  of  symptoms  and  impact  of  SGRQ  in  favor  of
S.20
A  recently  published  research  showed  different  results.
orty  patients  were  randomized  to  inhale  IS  or  HS  6%  daily
or  12  months  and  no  important  clinical  superiority  of  HS
ver  IS  was  identiﬁed.  Nevertheless,  there  were  signiﬁcant
mprovements  in  quality  of  life,  lung  function  and  sputum
olonization  in  both  groups.  Noteworthy  is  that  prior  to  the
rial  85%  of  the  patients  regularly  performed  airway  clear-
nce  techniques,  which  means  that  the  daily  use  of  a  saline
olution  may  offer  additional  beneﬁts.21
Even  though  there  is  some  evidence  favoring  HS,  it  seems
hat  both  hypertonic  and  isotonic  saline  are  beneﬁcial  in
on-CF  BE.19,21,21 These  results  agree  with  another  random-
zed  placebo-controlled  study  that  evaluated  the  clinical
tility  of  long-term  humidiﬁcation  therapy  in  108  patients
ith  COPD  (n  =  63)  or  BE  (n  =  45).  They  used  fully  humidiﬁed
igh  ﬂow  air  at  37 ◦C  through  nasal  cannulae,  daily,  over
 12-month  period.  The  patients  on  long-term  humidiﬁca-
ion  therapy  showed  signiﬁcantly  fewer  exacerbation  days,
ncreased  time  to  ﬁrst  exacerbation,  improvement  in  qual-
ty  of  life  and  lung  function.  There  was  a  non-signiﬁcant
eduction  in  exacerbation  frequency.22
-acetylcysteine
-acetylcysteine  (NAC)  is  commonly  used  in  the  treatment
f  BE  patients.  It  is  a  mucolytic  agent  that  disrupts  the
isulﬁde  bonds  in  mucus  when  inhaled.  After  oral  admin-
stration  there  is  no  NAC  in  airway  secretions  but  cysteine
s  detected  in  the  plasma  and  induces  an  increase  in  glu-
athione  levels  in  the  plasma  and  lung  which  has  antioxidant
roperties.  Therefore  the  beneﬁts  of  this  agent  may  come
rom  its  antioxidant  properties  and  not  its  mucolytic  charac-
eristics.  NAC  has  also  antibacterial  properties  by  reducing
he  ability  of  bacteria  to  adhere  to  epithelial  cells.23 Despite
his,  in  2001  a  Cochrane  review  concluded  that  there  is  no
vidence  to  recommend  the  use  of  NAC  in  non-CF  BE.24
Sputum  clearance  is  a  complex  mechanism,  with  sev-
ral  targets,  which  is  not  completely  understood.  Trials  of
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mucoactive  agents  are  scarce  and  there  are  some  discordant
results.  The  latter  may  be  explained  by  the  fact  that  the
analyses  are  usually  independent  of  the  underlying  disease.
With  sub-group  analyses,  clear  beneﬁts  would  probably  be
discovered,  which  underlines  the  importance  of  deﬁning  the
etiology.  An  example  of  this  is  the  bad  results  obtained  with
rhDNase  in  non-cystic  ﬁbrosis  BE,25 as  it  not  only  failed  to
improve  FEV1  but  also  the  patients  got  worse.
Anti-inﬂammatory therapy
As  stated  before,  persistent  inﬂammation  is  a  cardinal  fea-
ture  of  BE26;  it  is  part  of  a  vicious  cycle  which  also  involves
host  susceptibility,  sputum  hypersecretion,  airway  obstruc-
tion  and  infection.27 Sometimes,  even  in  the  absence  of
existing  infection  there  is  continuous  neutrophilic  inﬁltra-
tion  of  the  airways  which  suggests  dysregulation  of  immune
responses.28 In  this  setting,  it  is  reasonable  to  consider
anti-inﬂammatory  and/or  immunomodulatory  therapies  as
an  option  in  the  management  of  patients  with  BE.
Although  it  is  a  disease  which  is  increasingly  rec-
ognized  and  studied,  evidence  to  support  the  use  of
anti-inﬂammatory  therapies  is  still  limited  even  when  tak-
ing  into  account  drugs  with  an  established  anti-inﬂammatory
role  in  the  treatment  of  other  disorders.
Macrolides
Apart  from  their  antimicrobial  activity,  macrolides  have
been  increasingly  used  in  clinical  practice  for  the  treatment
of  a  variety  of  chronic  pulmonary  diseases  because  of  their
anti-inﬂammatory  and  immune-modulatory  properties.29--32
Although  solid  evidence  to  justify  long-term  macrolide  ther-
apy  in  many  of  these  disorders  is  still  lacking,  beneﬁcial
effects  have  been  found  in  small  clinical  trials  of  patients
with  non-CF  BE.33--39 There  were  considerable  variations  in
the  study  design  of  many  of  these  trials,  including  dura-
tion,  dose  and  macrolides  tested  and  outcome  measures
evaluated  but  most  of  them  showed  consistent  evidence
of  a  decrease  in  sputum  volume  and  some  reported  a
decrease  in  exacerbation  frequency.  Several  larger  stud-
ies  which  have  recently  been  completed  corroborate  these
ﬁndings.  A  signiﬁcant  reduction  in  exacerbation  frequency
was  found  in  the  preliminary  results  of  a  trial  with
89  patients  which  compared  the  use  of  azithromycin  with
a  placebo40 as  well  as  in  another  study  yet  to  be  published
with  117  patients  using  erythromycin.41 Accordingly,  the
largest  study  to  date,  which  has  recently  been  published,42
demonstrated  that  a  6  months  azithromycin  treatment  sig-
niﬁcantly  decreased  the  rate  of  exacerbations  requiring
antibiotic  therapy,  which  was  sustained  for  6  months  after
completion  of  treatment,  and  increased  the  time  to  the
ﬁrst  exacerbation  requiring  antibiotics.  As  well  as  these
beneﬁcial  effects,  however,  it  is  important  to  realize  that
side  effects  such  as  gastrointestinal  upset,  raised  transam-
inase  levels,  cardiac  arrhythmias  (particularly  prolonged
QT  interval  related),  auditory  impairment,  urogenital  can-
didiasis  and,  lastly,  and  possibly  most  importantly,  the
risk  of  microbial  macrolide  resistance,  particularly  non-
tuberculous  mycobacteria  (NMT),  may  occur.30,43
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Therefore,  macrolides  cannot  be  recommended  as  rou-
ine  therapy  for  non-CF  BE  before  further  research  is  carried
ut,  although  their  use,  particularly  azithromycin,  can  be
onsidered  in  selected  patients.4,44 In  patients  with  frequent
espiratory  exacerbations  or  continuous  symptoms  for  more
han  6  months,  particularly  if  chronically  infected  with  Pseu-
omonas  aeruginosa, a  trial  of  3--6  months  of  3  times  per
eek  250--500  mg  azithromycin  can  be  done  after  ruling  out
TM  infection.4,44 Transaminase  monitoring  should  be  per-
ormed  in  the  ﬁrst  few  weeks  of  treatment  and  then,  as  well
s  NTM  screening,  every  6  months  if  there  is  evidence  of  ben-
ﬁt  to  the  patient  in  terms  of  quality  of  life  and  frequency  of
xacerbations  and  the  therapy  is  not  discontinued.4 There
re  no  studies  to  support  either  the  effectiveness  or  safety
f  treatments  of  more  than  12  months  duration.
An  overview  of  the  available  studies  showing  the  effects
f  macrolides  in  patients  with  BE  is  presented  in  Table  2.
orticosteroids
espite  their  potent  anti-inﬂammatory  action,  long-term
ystemic  corticosteroids  cannot  be  used  due  to  poten-
ial  adverse  effects.  Inhaled  corticosteroids,  however,  have
een  studied  in  patients  with  BE  and  a  2009  review  by
apur  et  al.45 identiﬁed  six  randomized  clinical  trials  which
nrolled  278  of  303  randomized  adult  patients.  This  meta-
nalysis  concluded  that  there  was  insufﬁcient  evidence  to
ecommend  the  routine  use  of  inhaled  steroids  in  adults  with
table  state  BE  but  considered  that  a  therapeutic  trial  might
e  justiﬁed  in  patients  with  difﬁcult  to  control  symptoms;
hese  would  have  to  be  closely  monitored  for  adverse  events
specially  if  high  doses  were  used.
A  recently  published  Spanish  study46 reported  the  poten-
ially  beneﬁcial  effect  of  the  addition  of  a  long  acting  beta-2
drenergic  to  inhaled  corticosteroid  on  clinical  parameters
nd  health-related  quality  of  life  by  allowing  the  dose  of
he  inhaled  steroid  to  be  reduced  to  half  with  a reduction
f  local  side  effects.
These  ﬁndings  need  to  be  assessed  with  larger  controlled
andomized  trials.
ther  anti-inﬂammatory  agents
on-steroidal  anti-inﬂammatory  drugs  (NSAID)  may  also  be  a
otentially  attractive  therapy  in  patients  with  BE  as  ibupro-
en  has  demonstrated  beneﬁcial  effects  on  people  with
F.47,48 However,  two  Cochrane  Database  systemic  reviews
earching  for  use  of  oral49 and  inhaled  NSAID50 in  non-CF
E  only  identiﬁed  one  single  trial  of  inhaled  indomethacin
ersus  placebo  in  24  adults,  8  of  them  with  BE.  This  study
ocumented  a  signiﬁcant  reduction  in  sputum  production
nd  dyspnea  in  the  treatment  group  over  14  days  but  fur-
her  studies  on  the  efﬁcacy  of  NSAIDs  in  treating  patients
ith  BE  are  needed.
Like  macrolides,  another  class  of  drugs  that  have  recog-
ized  anti-inﬂammatory  and  immunomodulatory  properties
re  hydroxy-methyl-glutaryl-conzymeA  reductase  inhibitors
i.e.  statins)  which  have  demonstrated  in  vitro  inhibi-
ion  of  neutrophil  migration  and  epithelial  cell  production
f  chemoattractants  and  proteases  and  potentiation  of
acrophage  efferocytosis.51,52 As  efferocytosis  appears  to
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Table  2  Clinical  trials  of  macrolide  therapy.
Reference  Study  design  Number  of
patients;
Mean  age
Drug/dosage
Mean  duration
Beneﬁts  Adverse  effects  (number
of patients)
Koh  et  al.  (1997)33 Randomized,
double-blind,
placebo-controlled
25;
13  years
Roxithromycin:  4  mg/kg/12  h;
12 weeks
↓  Airway  hyperresponsiveness
↓  sputum  purulence
Not  studied
Tsang et  al.
(1999)34
Randomized,
double-blind,
placebo-controlled
21;
54.3  years
Erythromycin:  500  mg/12  h;
8 weeks
↑  EV1 and  FVC;
↓  sputum  volume
Rash  (1)
Davies et  al.
(2004)35
Prospective,
open  label
39;
51.9  years
Azithromycin:  500  mg/day  6  days,
followed  by  250  mg/day  for  6  days
and  later  250  mg/day,  3  days/week;
>4 months
↓  Volume  of  sputum
↓ Symptoms
↓  Exacerbations
↑  DLCO
Diarrhea  (2);
abnormal  liver  function
tests  (2);
rash  (1);
tinnitus  (1)
Cymbala et  al.
(2005)36
Randomized,
open  label,
crossover
11;
71  years
Azithromycin:  500  mg/day,
2 days/week;
6 months  +  6  months
↓  Volume  of  sputum
↓ Exacerbations
↑  General  well-being
Diarrhea  (3)
Yalcin et  al.
(2006)37
Randomized,
placebo-controlled
34;
12.5  years
Clarithromycin:  15  mg/kg/day;
3 months
↑  FEF25--75
↓  Volume  of  sputum
↓ Inﬂammatory  markers  in  BAL
ND
Anwar et  al.
(2008)38
Retrospective,
open  label
56;
63  years
Azithromycin:  250  mg/day,
3 days/week;
9.1  months
↑  FEV1
↓  Exacerbations
↓  Sputum  microbial  isolates
Diarrhea  (3)
abdominal  cramps  (2);
skin  rash  (1)
Serisier et  al.
(2011)39
Prospective,
open  label
21;
62.5  years
Erythromycin:  250  mg/day;
12 months
↓  Exacerbations
↓  Annual  days  of  antibiotic  use
Nausea  (1)
Headache  (1)
Alternburg et  al.
(2011)
BAT40
Randomized,
double-blind,
placebo-controlled
89;
65  years
Azithromycin:  250  mg/day;
12 months
↓  Exacerbations  ND
Serisier et  al.
(2012)
BLESS41
Randomized,
double-blind,
placebo-controlled
117;
62.3  years
Erythromycin:  250  mg/12  h;
12 months
↓  Exacerbations  QTc  prolongation  (1)
Wong et  al.  (2012)
EMBRACE42
Randomized,
double-blind,
placebo-controlled
141;
60  years
Azithromycin:  500  mg/day,
3 days/week;
6 months  +  6  months  follow-up
↓  Rate  of  exacerbations
↑  Time  to  ﬁrst  exacerbation
↓  Blood  neutrophils,  WBC
and  eosinophils
Macrolide  resistant
S.  pneumonia  (2)
Gastrointestinal
symptoms
BAT: Bronchiectasis and long-term Azithromycin Treatment; BLESS: Bronchiectasis and Low-dose Erythromycin Study; EMBRACE: Effectiveness of Macrolides in patients with BRonchiectasis
using Azithromycin to Control Exacerbations.
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tTherapy  of  non-cystic  ﬁbrosis  bronchiectasis  
be  involved  in  the  pathogenesis  of  a  variety  of  chronic  lung
and  systemic  inﬂammatory  disease  including  BE,  this  would
seem  an  attractive  target  for  statins  therapy.53 There  are
currently  ongoing  clinical  trials  to  evaluate  the  effect  of
atorvastatin  on  patients  with  BE,  with  and  without  P.  aeru-
ginosa  infection.54,55
Leukotriene  receptor  antagonists  may  theoretically  be  of
beneﬁt  as  they  inhibit  neutrophilic  mediated  inﬂammation
but  there  are  no  controlled  studies  to  date  to  support  their
use  in  BE.56
Methylxanthines  are  also  theoretically  of  use  in  BE  as  they
are  purported  to  have  anti-inﬂammatory  properties  but,
although  there  are  no  published  studies  to  date,57 there  are
trials  currently  underway  to  assess  the  effect  of  theophylline
in  the  treatment  of  bronchiectasis.58,59
Agents  speciﬁcally  targeting  a  particular  mediator  of  the
immune  response  might  be  an  interesting  new  class  of  drugs
in  the  future.  Roﬂumilast  and  speciﬁc  monoclonal  antibod-
ies,  e.g.  against  IL-8,  matrix  metalloproteases  (MMPs)  or
neutrophil  elastase,  are  in  this  group  but  the  safety  and  tol-
erability  of  these  drugs  still  need  to  be  assessed  in  phase  II
and  III  studies.
Antibiotic therapy
BE  provides  the  perfect  environment  for  colonization  by  var-
ious  microorganisms,  as  mucociliary  clearance  is  impaired,
facilitating  rapid  bacterial  growth  on  the  airways  mucosal
surface  without  tissue  invasion.
In  spite  of  the  fact  that  these  bacteria  do  not  cause  inva-
sive  disease  and  are  usually  less  virulent  than  those  that
invade  nearby  tissues,  they  are  able  to  trigger  an  inﬂam-
matory  response  that  aims  to  eliminate  the  microorganism;
when  this  purpose  fails,  however,  the  inﬂammation  becomes
chronic  and  leads  to  progressive  severe  lung  injury.
These  pathogens  can  also  develop  the  means  to  facilitate
their  own  survival,  overcoming  host  defence  mechanisms
and  antimicrobial  actions  through  bioﬁlm  production  and
other  bacterial  resistance  mechanisms.  Thus,  the  chronic
colonization  process  that  occurs  in  the  respiratory  tract
of  patients  with  BE  is  called  ‘‘pathogenic  colonization’’60
and  can  be  divided  into  three  different  phases:  initial  colo-
nization  (the  ﬁrst  isolate  of  a  microorganism),  intermittent
colonization  (intermittent  isolation  of  the  same  microorgan-
ism  in  cultures  separated  by,  at  least,  a  month,  representing
a  chronic  colonization  process  with  a  low  bacterial  load)  and
chronic  colonization  (three  or  more  successive  positive  cul-
tures  for  the  same  microorganism  with,  at  least,  one  month
apart,  within  a  period  of  six  months).60
Exacerbation  is  a  clinical  situation  that  can  happen  dur-
ing  any  of  the  three  scenarios  mentioned  above,  and  it
has  the  potential  to  worsen  lung  function  deterioration.60
The  diagnosis  of  exacerbation  in  these  patients  is  partic-
ularly  difﬁcult  and  is  based  on  the  acute  development  of
manifestations  such  as  changes  in  sputum  characteristics
(increased  volume,  purulence  and  viscosity),  haemoptysis,
breathlessness,  worsening  of  cough,  chest  pain,  fever,  asthe-
nia,  anorexia,  weight  loss,  physical  changes  in  thoracic
examination,  desaturation,  decline  in  lung  function,  radio-
logic  signs  of  lower  respiratory  tract  infection  and  elevation
of  systemic  biomarkers  of  inﬂammation.4
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Several  microorganisms  can  be  isolated  from  the  respira-
ory  tract  of  patients  with  non-CF  BE  and  the  acquisition  and
learance  of  a strain  is  a  complex,  dynamic  process  involv-
ng  host  factors  and  receptor  sites  on  the  organism  that  may
elp  deﬁne  its  ability  to  persist  and  damage  airways.  There  is
 slight  difference  in  the  dynamics  of  colonization  according
o  age.
The  most  frequently  isolated  pathogens  are  Haemophilus
nﬂuenzae,  P.  aeruginosa  and  Streptococcus  pneumonia.61,62
n  children  the  predominant  isolated  pathogen  is  H.
nﬂuenzae,60--65 whereas  in  adults,  although  H.  inﬂuenzae
s  still  the  most  frequently  isolated  pathogen,26,28,61 there
s  a  signiﬁcantly  higher  isolation  rate  of  P.  aeruginosa.62 S.
neumoniae  and  Moraxella  catharralis  are  also  found  in  a
igniﬁcant  but  variable  rate  and  Aspergillus  fumigatus  is
arely  isolated.62 Isolation  of  Staphylococcus  aureus  should
ead  to  consideration  of  underlying  CF.3,26,66
P.  aeruginosa  has  a  propensity  to  persist  in  bronchiectatic
irways  due  to  its  capacity  to  produce  virulence  factors  and
odulate  immune  defences  by  quorum  signaling  and  bioﬁlm
roduction.67
Since  infection  (and  particularly  P.  aeruginosa  infection)
lays  a  major  role  in  causing  and  perpetuating  BE,  reduc-
ng  the  microbial  load  using  antibiotics  is  a  cornerstone  of
herapy,68 either  through  treating  exacerbations  or  by  using
uppressive  antibiotic  strategies.
However,  the  isolation  of  one  or  more  pathogens  in  the
putum  of  patients  with  non-CF  BE  is  not  necessarily  an
ndication  for  antibiotic  treatment,  particularly  in  adults62;
here  are  three  main  criteria  for  prescribing  antibiotics  in
his  setting:  exacerbation,  eradication  of  the  ﬁrst  isolate
f  P.  aeruginosa  and  suppressive  therapy  in  steady-state  BE
hronically  colonized  with  P.  aeruginosa.
reatment  of  exacerbations
arly  treatment  of  exacerbations  is  particularly  important
s  it  could  probably  limit  the  vicious  circle  of  infec-
ion/inﬂammation  that  is  a  determinant  factor  of  lung
amage.
The  management  of  these  patients  includes  routine
ultures  of  respiratory  secretions  to  identify  infecting
rganisms  and  guide  antibiotic  selection  as  these  patients
requently  carry  the  same  bacteria  for  prolonged  periods
f  time.  The  current  recommendation  is  to  perform
ultures  every  three  months  on  average,  so  that  updated
nformation  is  available  to  guide  treatment  when  a  pul-
onary  exacerbation  occurs.4 Without  this  information  the
hoice  of  antibiotic  has  to  be  empirical,  based  on  the
ost  common  organisms  associated  with  exacerbations  in
hese  patients,  in  particular  P.  aeruginosa. Nevertheless,
efore  starting  antibiotic  therapy,  a  sputum  sample  should
e  sent  off  for  culture,  after  which  antibiotics  should  be
tarted  and  then  eventually  changed  in  accordance  with
he  microorganism  isolated  and  its  antibiogram.  However,
n  vitro  antibiotic  sensitivity  does  not  always  correlate  with
herapeutic  response,  which  happens  with  microorganisms
ble  to  form  a  bioﬁlm,  where  the  activity  of  many  antibi-
tics  is  diminished.69 So,  although  an  antibiogram  is  essential
or  guiding  treatment,  the  value  of  conventional  in  vitro
usceptibility  testing  for  these  patients  is  being  questioned.
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It  is  also  common  to  isolate  more  than  one  microrganism
r  distinct  morphotypes  of  the  same  pathogen  with  the  same
r  different  patterns  of  antimicrobial  sensitivity.  Selecting
n  antibiotic  combination  that  covers  all  the  isolates  can  be
ifﬁcult  without  resorting  to  an  impractically  large  number
f  antibiotics.
The  route  of  administration  will  depend  on  the  sever-
ty  of  the  exacerbation  and  the  evidence  of  colonization  by
ultidrug  resistant  microorganisms.
Mild  exacerbations  can  be  treated  orally  with  a  ﬂuo-
oquinolone  on  an  outpatient  basis.70,71 The  addition  of
nhaled  tobramycin  solution  (TS)  to  ciproﬂoxacin  was  stud-
ed  because  of  concerns  regarding  virulence  and  potential
esistance  of  Pseudomonas. In  a  double-blind,  multicenter
rial,  53  patients  with  non-CF  BE  and  respiratory  exacerba-
ions  due  to  Pseudomonas  were  randomly  assigned  to  receive
iproﬂoxacin  plus  TS  or  plus  placebo  for  two  weeks.72 The
ddition  of  TS  did  not  improve  clinical  outcomes  although
here  was  a  marked  reduction  of  Pseudomonas  density  in  the
putum.  Based  on  this,  TS  cannot  be  recommended  alone  or
n  combination  with  ciproﬂoxacin  for  acute  exacerbations  in
on-CF  BE.
Intravenous  therapy  is  reserved  for  oral  therapy  fail-
re,  severe  exacerbations  or  microorganisms  resistant  to
ral  antibiotics.  The  most  commonly  selected  intravenous
egimen  combines  two  antibiotics  (usually  a  -lactam
nti-Pseudomonas:  piperacillin-tazobactam,  ceftazidime  or
eropenem)  and  an  aminoglycoside.60,70 The  rationale  for
hoosing  two  rather  than  one  is  based  on  the  possibility  of
btaining  synergic  effects  and  decreasing  the  risk  of  antibi-
tic  resistances.  Regarding  the  aminoglycoside,  tobramycin
s  recommended  due  to  its  strong  activity  against  P.  aeru-
inosa  compared  to  other  aminoglycosides.  In  cases  of
obramycin  resistance,  amikacin  can  be  used.
Adding  an  inhaled  antibiotic  to  an  intravenous  one  has
ot  been  shown  to  provide  clinical  beneﬁts.73
There  is  no  evidence  to  recommend  combination  antibi-
tics  in  patients  colonized  with  microorganisms  other  than
.  aeruginosa, unless  there  is  more  than  one  pathogen.
Exacerbations  should  be  treated  using  a  high  dosage  tar-
eted  antibiotic  therapy,3,4 due  to  the  fact  that  the  volume
f  distribution  and  total  body  clearance  for  hydrophilic  drugs
such  as  aminoglycosides,  penicillins,  and  cephalosporins)
re  increased  because  these  patients  are  generally  under-
ourished  and  have  decreased  adipose  tissue.
The  duration  of  antibiotic  therapy  is  also  a  matter
f  debate  requiring  further  investigation  but  the  expert
onsensus  is  that  14  days  should  be  recommended  for  all
xacerbations.3,4,60,69
reatment  of  Pseudomonas  aeruginosa
nfection/colonization
s  the  disease  progresses  chronic  infection  by  P.  aerugin-
sa  becomes  common  and  it  seems  to  be  an  independent
isk  factor  for  accelerated  loss  of  pulmonary  function  and
ecreased  survival.  Conversion  of  P.  aeruginosa  to  the
ucoid  phenotype  worsens  prognosis  although  it  is  more
ommon  in  patients  with  CF.74,75
Although  there  are  no  studies  to  guide  practice  following
he  ﬁrst  isolation,  an  attempt  to  eradicate  seems  pragmatic
or  what  it  should  be  treated  aggressively  regardless  of  the
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atient’s  clinical  signs  or  symptoms  in  order  to  eliminate  the
icroorganism  from  the  sputum  as  it  is  very  difﬁcult  to  do
o  once  chronic  colonization  is  established.3,4
In  non-CF  BE  the  strategy  proposed  for  eradication  is
ral  ciproﬂoxacin  for  3  weeks  and  if  it  fails,  the  same
rotocol  as  for  CF  is  recommended  (nebulized  antibiotic:
obramycin,  sodium  colistimethate  or  aztreonam  lysine)  plus
ral  ciproﬂoxacin  for  3  weeks,  followed  by  inhaled  antibi-
tics  for  3--12  months.4,60,76 An  alternative  would  be  an
ssociation  of  2  anti-Pseudomonas  intravenous  antibiotics
or  14--21  days,  followed  by  an  inhaled  antibiotic  for  3--
2  months.4,60,76 As  was  stated  above,  an  antibiogram  is
ssential  for  guiding  treatment  although  it  is  recognized
hat  in  vitro  sensitivity  does  not  always  correlate  with  ther-
peutic  response.  However,  for  nebulized  antibiotics  the
nterpretation  of  the  antibiogram  should  take  into  consider-
tion  that,  through  this  form  of  delivery,  antibiotic  achieves
uch  higher  concentrations  in  the  bronchial  mucosa  over-
oming  the  mechanisms  of  resistance.77
The  persistence  of  bacteria  despite  aggressive  treatment
s  thought  to  be  due  to  several  factors  such  as  poor  pene-
ration  of  antibiotics  into  purulent  airway  secretions,  native
r  acquired  antibiotic  resistance  and  production  of  bioﬁlms
y  the  bacteria  that  may  render  antibiotics  ineffective  or
nterfere  with  host  defences.
To  prevent  the  decline  in  lung  function  associated  to
hronic  bronchial  colonization  with  this  pathogen,  nebulized
ntibiotics  that  show  in  vitro  activity  against  P.  aeruginosa
re  frequently  used  as  chronic  suppressive  therapy.  The  aim
f  this  strategy  is  to  reduce  the  bacterial  burden  (as  in  this
hase  it  is  virtually  impossible  to  eradicate  the  pathogen)
nd,  thus,  reduce  the  inﬂammatory  response  that  leads  to
tructural  lung  damage  and  loss  of  function,4,78 avoiding
he  cumbersome  and  toxic  iatrogenic  effects  associated  to
ral  or  intravenous  route.79 It  seems  that  this  strategy  may
educe  the  frequency  and  severity  of  respiratory  exacerba-
ions  and  the  decline  in  lung  function.80,81
One  trial  conducted  in  2000  randomly  assigned
4  patients  with  non-CF  BE  and  P.  aeruginosa  infec-
ion  to  receive  aerosolized  tobramycin  (300  mg,  twice
aily)  or  aerosolized  placebo  for  28  days.80 Patients  in  the
reatment  group  demonstrated  a  10,000-fold  reduction  in
seudomonas  density,  but  no  change  in  FEV1  as  compared
o  controls.  The  same  results  were  attained  in  a  similar
rial  conducted  in  2001.82
In  2005,  a 6  month  double  blind  crossover  study  of  aerosol
obramycin  was  carried  out  on  30  patients  and  revealed  no
hange  in  exacerbation  rate,  but  the  number  of  hospitaliza-
ions  and  duration  of  hospital  stay  were  reduced  during  the
obramycin  phase.83
In  2005  a smaller  uncontrolled  study  was  carried  out
n  which  aerosolized  tobramycin  (300  mg,  twice  daily)  was
dministered  to  41  patients  with  non-CF  BE  and  Pseu-
omonas  infection;  the  protocol  alternated  two  weeks
ith  therapy  and  two  weeks  without,  for  a  total  of  12
eeks.84 Treatment  was  associated  with  a  decrease  in  symp-
oms  and  improvements  in  health-related  quality  of  life
QOL).  However,  10  of  41  patients  were  unable  to  com-
lete  the  protocol  because  of  side  effects  (cough,  wheezing
r  worsened  dyspnea),  and  two  of  the  patients  who  com-
leted  the  trial  acquired  tobramycin-resistant  Pseudomonas
pecies.
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1Therapy  of  non-cystic  ﬁbrosis  bronchiectasis  
In  2007  an  uncontrolled  study  examined  the  efﬁcacy  of
nebulized  colistin  in  a  mixed  population  of  patients  with
COPD  and  bronchiectasis  colonized  with  PSAE  and  showed
an  improvement  in  quality  of  life  and  slower  decline  with
FEV1  with  treatment.85
Currently,  many  other  clinical  trials  are  being  carried  out
with  the  purpose  of  establishing  the  indications  for  inhaled
antibiotic  therapy  in  these  patients  and  deﬁne  which  antibi-
otics  to  use  and  the  most  appropriate  devices  to  deliver
them.86
In  fact,  at  the  moment,  the  clinical  evidence  that  sup-
ports  the  use  of  chronic  inhaled  antibiotherapy  in  non-CF  BE,
chronically  colonized  with  Pseudomonas, is  scarce  but  all  the
data  suggest  that  this  therapeutic  strategy  seems  to  control
the  symptoms,  prevent  the  progression  of  the  disease  and
reduce  the  morbidity  with  no  relevant  adverse  events.87,88
The  chronic  antibiotherapy  may  be  intermittent  (28  days
on,  28  days  off)  when  using  tobramycin  or  aztreonam  lysine
or  continuous  when  using  sodium  colistimethate.  However,
continuous  inhaled  antibiotherapy  should  be  prescribed
using  2  different  antibiotics  alternately  in  patients  that
are  very  symptomatic  in  off-periods,  or  with  severe  lung
function  impairment  or  recurrent  pulmonary  exacerbations
despite  taking  one  antibiotic  every  other  month.4
Nevertheless,  there  is  still  a  degree  of  uncertainty  about
when  to  prescribe  the  various  inhaled  antibiotics  and  what
to  choose.
At  the  moment  the  recommendations3 are  to  treat
patients  with  non-CF  BE  chronically  colonized  with  P.  aeru-
ginosa  and  with  frequent  acute  exacerbations  (three  or  more
per  year)  or  progressive  deterioration  of  lung  function,  with
inhaled  antibiotics;  it  seems  reasonable  to  use  tobramycin
as  the  ﬁrst  choice  because  of  the  extensive  information  sup-
porting  its  efﬁcacy  and  good  safety  record  after  many  years
of  use.  The  level  of  evidence  and  clinical  beneﬁt  is  greatest
for  patients  with  moderate  or  severe  lung  disease.
The  option  for  inhaled  aztreonam  instead  of  tobramycin
may  be  considered  if  there  is  evidence  of  inhaled
tobramycin  intolerance,  clinical  deterioration  despite
inhaled  tobramycin,  a  strong  possibility  of  increasing  adher-
ence  due  to  the  fact  that  inhaled  aztreonam  can  be
delivered  more  rapidly  than  tobramycin  and  evidence  or
possibility  of  pregnancy  when  aminoglycosides  are  relatively
contraindicated.  Data  are  needed  from  well-designed  com-
parative  effectiveness  trials  for  tobramycin  and  aztreonam
to  provide  for  a  more  informed  decision  as  to  which  to  use.
Given  the  less  than  robust  data  supporting  its  use  and
the  suggestion  that  it  may  be  inferior,  it  seems  reasonable
to  prescribe  colistin  only  in  cases  of  tobramycin  therapeutic
failure  or  intolerance.
In  conclusion,  controlling  respiratory  infec-
tion/colonization  is  the  cornerstone  of  therapy  in  non-CF
BE  with  a  signiﬁcant  impact  on  survival  for  which  more
robust  data  are  needed  to  support  decisions  in  this  area.
ConclusionBE  has  recently  became  a  hot  topic.  First  results  of  well
designed  trials  have  been  published  and  several  studies  are
in  progress.  However,  there  are  many  questions  regarding
treatment  which  are  still  waiting  for  scientiﬁc  answers.
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It  will  be  important  to  design  studies  involving  a greater
umber  of  patients,  with  different  levels  of  severity,  more
peciﬁc  aetiological  information  and  carried  out  over  longer
ime  periods  to  clarify  the  real  beneﬁts  of  these  promising
herapies  and  bring  new  insights  into  this  interesting  topic.
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